Pancreatic cancer: Long overdue for a new treatment approach
Despite advances in treatments for other cancers, mortality rates in pancreatic cancer have remained unchanged for more than 30 years. For all stages combined, 5-year relative survival is just 7%.1
Indoximod is making strides in metastatic pancreatic cancer research2
NewLink Genetics’ indoximod is a small-molecule indoleamine 2,3-dioxygenase (IDO) pathway inhibitor that has the potential to disrupt mechanisms by which tumors evade the immune system.3,4
1. American Cancer Society. Cancer facts and figures 2015. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf. Accessed October 3, 2015. 2. National Institutes of Health. Study of IDO inhibitor in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer. http://clinicaltrials.gov/ct2/show/record/NCT02077881. Accessed October 4, 2015. 3. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013;34(3):137-143. 4. Baban B, Chandler PR, Sharma MD, et al. IDO activates regulatory T cells and blocks their conversion into Th17-like helper T cells. J Immunol. 2009;183(4):2475-2483.